The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Germline variation and risk of immune-related adverse events (irAEs): A real-world BioVU study.
 
Justin M. Balko
Stock and Other Ownership Interests - Beam Therapeutics; BioNano Genomics; crispr therapeutics
Consulting or Advisory Role - AstraZeneca; Lilly; Malinkrodt; Pfizer
Research Funding - Genentech/Roche; Incyte
Patents, Royalties, Other Intellectual Property - FCRL6 as an immunotherapy target; Patent on use of HLA-DR/MHC expression to predict response to immunotherapies
Other Relationship - NanoString Technologies
 
Lydia Yao
No Relationships to Disclose
 
Siwei Zhang
No Relationships to Disclose
 
Catherine Fahey
Honoraria - AJMC’s Institute for Value-Based Medicine
 
Alexandra Haugh
No Relationships to Disclose
 
Andrea Davis
No Relationships to Disclose
 
Eric Mukherjee
Consulting or Advisory Role - AERMED
 
Christian Hammer
Employment - Altos Labs; Genentech/Roche; Genentech/Roche (I)
Stock and Other Ownership Interests - enentech / Roche, Altos Labs; enentech / Roche, Altos Labs (I)
Patents, Royalties, Other Intellectual Property - enentech / Roche, Altos Labs
 
Elizabeth J Phillips
No Relationships to Disclose
 
Cosmin A Bejan
No Relationships to Disclose
 
Yaomin Xu
No Relationships to Disclose
 
Douglas Buckner Johnson
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck; Mosaic ImmunoEngineering; Novartis; Pfizer; Targovax
Research Funding - Bristol-Myers Squibb; Incyte
Patents, Royalties, Other Intellectual Property - Abatacept for the use of immune related adverse events.; Intellectual property and patents pending surrounding use of MHC-II and response to immune therapy